We believe that MBI has the potential to revolutionize the way breast cancer is detected and diagnosed by overcoming the limitations of existing technologies
Tucson, AZ (Vocus) September 14, 2010
Radiology portal AuntMinnie.com today announced the launch of Advances in Molecular Breast Imaging, a new Special Report exclusively devoted to information about one of the most exciting new technologies in medical imaging.
Molecular breast imaging (MBI) involves the use of a dedicated gamma camera with digital detectors to detect breast cancer. Advocates of the technology believe that it will have a role as a complement to screening mammography for diagnosing suspicious breast lesions, particularly in younger women with dense breast tissue.
Advances in Molecular Breast Imaging is being sponsored by Gamma Medica, Inc. (GMI), which launched its LumaGEM™ MBI scanner this year. The LumaGEM™ MBI System is the first commercially available, FDA-cleared, planar, dual-head, fully solid state digital imaging system utilizing cadmium zinc telluride (CZT) technology used for breast imaging. This technology was co-developed and licensed from the Mayo Clinic of Rochester, MN.
"We believe that MBI has the potential to revolutionize the way breast cancer is detected and diagnosed by overcoming the limitations of existing technologies," said Dr. Bradley Patt, CEO of Gamma Medica. "Dense breast tissue can make mammograms difficult to interpret, but MBI isn't affected by breast density. This makes the technology particularly beneficial for younger women ages 40-50, for whom mammography screening is controversial."
AuntMinnie.com's Special Report format of in-depth articles focusing on a particular topic is well-suited to MBI, which is a relatively new technology, according to Ashok Shah, AuntMinnie.com general manager.
"We're pleased that Gamma Medica chose Advances in Molecular Breast Imaging as a platform for disseminating their message to the radiology community," Shah said. "Medical imaging professionals can learn about MBI through the experiences of their peers, and use that information to make the right decision about what's best for their patients."
Advances in Molecular Breast Imaging can be accessed through the main AuntMinnie.com Web page, or by visiting http://mbi.auntminnie.com.
AuntMinnie.com is the premier online information, transaction, and education site for all individuals affiliated with the medical imaging market. Rich in timely, original content and customer-centered products and services, AuntMinnie.com is designed to enhance the professional lives of its members through interaction, participation, exchange, and commerce. AuntMinnie.com is owned by IMV, Ltd. Additional information on AuntMinnie.com is available at http://www.auntminnie.com.
About Gamma Medica, Inc.
Gamma Medica (http://www.gm-ideas.com) designs, builds and services imaging systems based on novel technologies to improve patient health through early diagnosis of disease, improved patient treatment and by enabling new drug discovery. Gamma Medica is dedicated to leading medical imaging into a new digital era with its unique sensor readout systems. The company’s core digital imaging technologies also hold great promise for a new class of solutions for the safety and security markets.
In the company’s Pre-Clinical Division, Gamma Medica’s flagship product, the FLEX Triumph™ imaging platform, is marketed for medical research and drug development. The FLEX Triumph system combines PET (LabPET™), SPECT (X-SPECT®) and CT (X-O™) modalities in the world’s first tri-modality system. Gamma Medicas pre-clinical imaging products are distributed exclusively by GE Healthcare globally and in Japan by SII NanoTechnology, a Seiko company.
In the Clinical Division, Gamma Medica offers the LumaGEM™ MBI System. As the first commercially available, FDA cleared, planar, dual head, fully solid state digital imaging system utilizing cadmium zinc telluride (CZT) technology used for breast imaging, LumaGEM is able to detect millimeter-size breast cancers missed by mammography, especially in women with dense breast tissue.
# # #